No quarterly revenue total was found in Processa Pharmaceuticals, Inc.'s SEC filings.
Processa Pharmaceuticals, Inc. (PCSA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-3.27M
+17.0% vs year-ago quarter
Operating cash flow
$-2.00M
+12.1% vs year-ago quarter
Free cash flow
$-2.25M
+37.7% vs prior quarter
EPS
$-1.19
+81.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.79M
-94.5% vs year-ago quarter
Net cash
$6.91M
Q2 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vero Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1533743
- Former names
- Heatwurx, Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.3M | -$3.3M | -$3.7M | -$3.5M | -$4.0M |
| Net income | -$3.3M | -$3.4M | -$3.4M | -$3.4M | -$3.9M |
| Diluted EPS | -$1.19 | -$1.29 | $0.05 | -$0.07 | -$6.26 |
| Operating cash flow | -$2.0M | -$3.6M | -$2.9M | -$3.5M | -$2.3M |
| Total assets | $2.1M | $4.5M | $7.8M | $7.6M | $8.2M |
| Total liabilities | $2.4M | $2.0M | $2.2M | $1.8M | $2.1M |
| Stockholders' equity | -$317,341 | $2.5M | $5.6M | $5.8M | $6.1M |
| Cash and investments | $196,325 | $1.7M | $5.5M | $6.3M | $6.9M |
| Total debt | — | — | — | — | $25,584 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K/A |
Amended current report
Other events
|
Oct 5, 2026 | Jul 23, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Aug 4, 2026 | Jul 30, 2026 |
All 705 Processa Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.